

# Barbara Altieri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8433764/publications.pdf>

Version: 2024-02-01

92  
papers

1,821  
citations

279798

23  
h-index

315739

38  
g-index

104  
all docs

104  
docs citations

104  
times ranked

2373  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 335-346.  | 5.7  | 134       |
| 2  | Vitamin D and chronic diseases: the current state of the art. <i>Archives of Toxicology</i> , 2017, 91, 97-107.   | 4.2  | 108       |
| 3  | Shedding new light on female fertility: The role of vitamin D. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 273-283.   | 5.7  | 98        |
| 4  | Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4511-4523.  | 3.6  | 92        |
| 5  | Vitamin D testing: advantages and limits of the current assays. <i>European Journal of Clinical Nutrition</i> , 2020, 74, 231-247.  | 2.9  | 81        |
| 6  | Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4323-4332.   | 3.6  | 79        |
| 7  | Vitamin D and pancreas: The role of sunshine vitamin in the pathogenesis of diabetes mellitus and pancreatic cancer. <i>Critical Reviews in Food Science and Nutrition</i> , 2017, 57, 3472-3488.   | 10.3 | 77        |
| 8  | Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. <i>Nutrients</i> , 2018, 10, 1854.   | 4.1  | 61        |
| 9  | Next-generation therapies for adrenocortical carcinoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101434.  | 4.7  | 61        |
| 10 | Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. , 2020, 8, e000469.  |      | 59        |
| 11 | Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 499-508. | 11.4 | 55        |
| 12 | CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. <i>PLoS ONE</i> , 2014, 9, e105855.  | 2.5  | 41        |
| 13 | S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. <i>European Journal of Endocrinology</i> , 2022, 186, 25-36.   | 3.7  | 41        |
| 14 | Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors &lt; 2 Centimeters. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 78-84.  | 3.6  | 39        |
| 15 | Nutrition and neuroendocrine tumors: An update of the literature. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 159-167.  | 5.7  | 38        |
| 16 | Patient empowerment and the Mediterranean diet as a possible tool to tackle prediabetes associated with overweight or obesity: a pilot study. <i>Hormones</i> , 2019, 18, 75-84.  | 1.9  | 37        |
| 17 | Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3491-3498.  | 3.6  | 33        |
| 18 | Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. <i>Journal of Clinical Medicine</i> , 2019, 8, 1850.   | 2.4  | 31        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Adrenocortical tumors and insulin resistance: What is the first step?. International Journal of Cancer, 2016, 138, 2785-2794.  | 5.1  | 29        |
| 20 | Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. Cancers, 2019, 11, 1332.  | 3.7  | 28        |
| 21 | Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. Cancers, 2020, 12, 740.  | 3.7  | 28        |
| 22 | Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. Endocrine-Related Cancer, 2015, 22, 531-543.  | 3.1  | 27        |
| 23 | Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. Frontiers in Endocrinology, 2021, 12, 649496.              | 3.5  | 27        |
| 24 | Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. Oncotarget, 2017, 8, 9323-9338.  | 1.8  | 27        |
| 25 | Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine, 2020, 69, 441-450.   | 2.3  | 26        |
| 26 | The role of insulin-like growth factor system in the adrenocortical tumors. Minerva Endocrinologica, 2018, 44, 43-57.  | 1.8  | 25        |
| 27 | Nutritionist and obesity: brief overview on efficacy, safety, and drug interactions of the main weight-loss dietary supplements. International Journal of Obesity Supplements, 2019, 9, 32-49. | 12.6 | 24        |
| 28 | RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4459-e4473.                    | 3.6  | 24        |
| 29 | Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. Frontiers in Endocrinology, 2020, 11, 219.                            | 3.5  | 23        |
| 30 | Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. Cancers, 2020, 12, 359.                | 3.7  | 23        |
| 31 | Chronotype and cardio metabolic health in obesity: does nutrition matter?. International Journal of Food Sciences and Nutrition, 2021, 72, 892-900.  | 2.8  | 22        |
| 32 | Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk. Current Vascular Pharmacology, 2019, 17, 610-617.   | 1.7  | 22        |
| 33 | Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma. Frontiers in Endocrinology, 2020, 11, 597878.   | 3.5  | 18        |
| 34 | Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2642-2653.      | 3.6  | 18        |
| 35 | Adrenal disorders: Is there Any role for vitamin D?. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 355-362.  | 5.7  | 17        |
| 36 | Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. Nutrients, 2020, 12, 1021.  | 4.1  | 17        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | The Importance of Being a "Lark"™ in Post-Menopausal Women with Obesity: A Ploy to Prevent Type 2 Diabetes Mellitus?. <i>Nutrients</i> , 2021, 13, 3762.                          | 4.1 | 17        |
| 38 | Current evidence on vitamin D deficiency and kidney transplant: What's new?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 323-334.                             | 5.7 | 15        |
| 39 | ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. <i>European Journal of Endocrinology</i> , 2018, 178, 181-188.                         | 3.7 | 15        |
| 40 | Management of Patients With Glucocorticoid-Related Diseases and COVID-19. <i>Frontiers in Endocrinology</i> , 2021, 12, 705214.   | 3.5 | 15        |
| 41 | What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. <i>Journal of Personalized Medicine</i> , 2021, 11, 269.           | 2.5 | 14        |
| 42 | ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus. <i>European Journal of Endocrinology</i> , 2020, 183, R197-R215.        | 3.7 | 14        |
| 43 | An Italian Survey of Compliance With Major Guidelines for L-Thyroxine of Primary Hypothyroidism. <i>Endocrine Practice</i> , 2018, 24, 419-428.                                   | 2.1 | 13        |
| 44 | From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 511-525. | 5.7 | 13        |
| 45 | Identifying New Potential Biomarkers in Adrenocortical Tumors Based on mRNA Expression Data Using Machine Learning. <i>Cancers</i> , 2021, 13, 4671.                              | 3.7 | 12        |
| 46 | Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives. <i>Endocrine</i> , 2018, 62, 506-516.   | 2.3 | 11        |
| 47 | Circulating microRNA Expression in Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2021, 12, 620012.  | 3.5 | 11        |
| 48 | Canine insulinoma as a model for human malignant insulinoma research: Novel perspectives for translational clinical studies. <i>Translational Oncology</i> , 2022, 15, 101269.    | 3.7 | 8         |
| 49 | Sex differences in carcinoid syndrome: A gap to be closed. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 659-669.   | 5.7 | 7         |
| 50 | Leydig Cell Tumour and Giant Adrenal Myelolipoma Associated with Adrenogenital Syndrome: A Case Report with a Review of the Literature. <i>Urologia</i> , 2016, 83, 43-48.        | 0.7 | 6         |
| 51 | Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors. <i>Endocrine</i> , 2022, 75, 623-634.  | 2.3 | 6         |
| 52 | Chronic low-dose glucocorticoid inhalatory therapy as a cause of bone loss in a young man: case report. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2013, 10, 199-202. | 1.0 | 6         |
| 53 | FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. <i>Endocrine</i> , 2022, 77, 411-418.        | 2.3 | 6         |
| 54 | Epithelial and Mesenchymal Markers in Adrenocortical Tissues: How Mesenchymal Are Adrenocortical Tissues?. <i>Cancers</i> , 2021, 13, 1736.                                       | 3.7 | 5         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Case Report: Consecutive Adrenal Cushing's Syndrome and Cushing's Disease in a Patient With Somatic CTNNB1, USP8, and NR3C1 Mutations. <i>Frontiers in Endocrinology</i> , 2021, 12, 731579. | 3.5 | 5         |
| 56 | Bone metabolism, bone mass and structural integrity profile in professional male football players. <i>Journal of Sports Medicine and Physical Fitness</i> , 2020, 60, 912-918.               | 0.7 | 5         |
| 57 | Low bone mineral density in a growth hormone deficient (GHD) adolescent. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2013, 10, 203-5.   | 1.0 | 5         |
| 58 | A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. <i>Cancers</i> , 2021, 13, 5831.                                 | 3.7 | 5         |
| 59 | Integrative genomic analysis reveals a conserved role for prolactin signalling in the regulation of adrenal function. <i>Clinical and Translational Medicine</i> , 2021, 11, e630.           | 4.0 | 4         |
| 60 | Targeted molecular analysis in adrenocortical carcinomas: a strategy towards improved personalized prognostication. <i>Endocrine Abstracts</i> , 0, , .                                      | 0.0 | 2         |
| 61 | Mitotane treatment in adrenocortical carcinoma: mechanisms of action and predictive markers of response to therapy. <i>Minerva Endocrinology</i> , 2021, , .                                 | 1.1 | 2         |
| 62 | Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications. <i>Frontiers in Endocrinology</i> , 2021, 12, 795116.                               | 3.5 | 2         |
| 63 | Modified GRAS Score for Prognostic Classification of Adrenocortical Carcinoma: An ENSAT Multicentre Study. <i>Journal of the Endocrine Society</i> , 2021, 5, A165-A166.                     | 0.2 | 1         |
| 64 | Cytochrome P450 (CYP) 2W1 affect steroid secretion in adrenocortical cell line and tumor tissues. <i>Endocrine Abstracts</i> , 0, , .  | 0.0 | 1         |
| 65 | Targeted molecular analysis in adrenocortical carcinomas: a way towards improved personalized prognostication. <i>Endocrine Abstracts</i> , 0, , .   | 0.0 | 1         |
| 66 | New cancer drug targets identified in adrenocortical carcinoma through gene expression profiling. <i>Endocrine Abstracts</i> , 0, , .  | 0.0 | 1         |
| 67 | Lanreotide therapy vs wait-and-see in patients with pancreatic neuroendocrine tumors. <i>Endocrine Abstracts</i> , 0, , .  | 0.0 | 1         |
| 68 | RNA-sequencing of adrenocortical tumors reveals novel pathogenetic insights. <i>Endocrine Abstracts</i> , 0, , .   | 0.0 | 1         |
| 69 | SUN-LB22 PLK1 as a New Treatment Target for Adrenocortical Carcinoma. <i>Journal of the Endocrine Society</i> , 2020, 4, .   | 0.2 | 1         |
| 70 | Adverse events of mitotane treatment in patients with adrenocortical carcinoma. <i>Endocrine Abstracts</i> , 0, , .  | 0.0 | 0         |
| 71 | Circulating cell-free DNA for prognostication and disease surveillance in adrenocortical carcinoma. <i>Endocrine Abstracts</i> , 0, , .  | 0.0 | 0         |
| 72 | Evaluation of the Molecular Pathogenesis of Adrenocortical Tumors by Whole-Genome Sequencing. <i>Journal of the Endocrine Society</i> , 2021, 5, A68-A68.                                    | 0.2 | 0         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Clinical and penile Doppler outcomes using a modified, tourniquet free, Nesbit plication for severe Peyronie's disease. Translational Andrology and Urology, 2021, 10, 2857-2870.                     | 1.4 | 0         |
| 74 | The Notch ligand Jagged1 is up-regulated in adrenocortical carcinomas and is associated with a favourable clinical outcome. Endocrine Abstracts, 0, , .   | 0.0 | 0         |
| 75 | Inhibitor of apoptosis protein livin/BIRC7 in adrenocortical tumours. Endocrine Abstracts, 0, , .   | 0.0 | 0         |
| 76 | CYP2W1*6 polymorphism as a potential predictive marker of sensitivity to mitotane treatment in adrenocortical carcinoma. Endocrine Abstracts, 0, , .  | 0.0 | 0         |
| 77 | Epithelial to mesenchymal transition in adrenocortical tumours: focus on FGF-FGFR pathway and c-MET. Endocrine Abstracts, 0, , .  | 0.0 | 0         |
| 78 | Germline CYP2W1*6 polymorphism is a new predictive marker of sensitivity to mitotane treatment in advanced adrenocortical carcinoma: a multicenter European study. Endocrine Abstracts, 0, , .        | 0.0 | 0         |
| 79 | Mesenchymal tissue markers as potential drug targets in adrenocortical tumours. Endocrine Abstracts, 0, , .   | 0.0 | 0         |
| 80 | Germline CYP2W1*6 and CYP2B6*6 polymorphisms as predicting markers of sensitivity to mitotane treatment in advanced adrenocortical carcinoma: a multicentric ENSAT study. Endocrine Abstracts, 0, , . | 0.0 | 0         |
| 81 | SUN-350 Sterol-O-Acyl Transferase 1 Protein Expression Alone Is Not Sufficient to Predict Response to Mitotane Treatment in Adrenocortical Carcinoma. Journal of the Endocrine Society, 2019, 3, .    | 0.2 | 0         |
| 82 | Cyclin dependent kinase 4 as promising drug target in adrenocortical carcinoma. Endocrine Abstracts, 0, , .   | 0.0 | 0         |
| 83 | Neuroendocrine neoplasms (NEN) arising in uncommon sites: epidemiological and clinical features. Endocrine Abstracts, 0, , .  | 0.0 | 0         |
| 84 | Management of adjuvant mitotane therapy for adrenocortical carcinoma: a survey in Italy. Endocrine Abstracts, 0, , .  | 0.0 | 0         |
| 85 | Vitamin D deficiency is a predictor marker of tumor aggressiveness in sporadic and MEN1-related well-differentiated, low-grade GEP-NET. Endocrine Abstracts, 0, , .                                   | 0.0 | 0         |
| 86 | PLK1 inhibitors as potential new treatment for adrenocortical carcinoma. Endocrine Abstracts, 0, , .  | 0.0 | 0         |
| 87 | Sporadic neuroendocrine neoplasms in young-adult patients: Differences in natural history, prognosis and treatment compared to adult-elderly patients. Endocrine Abstracts, 0, , .                    | 0.0 | 0         |
| 88 | Modified GRAS score for prognostic classification of adrenocortical carcinoma: an ENSAT multicentre study. Endocrine Abstracts, 0, , .  | 0.0 | 0         |
| 89 | Adverse events associated to mitotane treatment in patients with adrenocortical carcinoma. Endocrine Abstracts, 0, , .  | 0.0 | 0         |
| 90 | Consecutive adrenal cushing's syndrome and cushing's disease in a patient with somatic CTNNB1, USP8, and NR3c1 mutations. Endocrine Abstracts, 0, , .   | 0.0 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 91 | PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma. Endocrine Abstracts, 0, , .                                  | 0.0 | 0         |
| 92 | Circulating cell-free DNA-based biomarkers as a tool for disease surveillance in adrenocortical carcinoma. Endocrine Abstracts, 0, , . | 0.0 | 0         |